RecruitingPhase 2NCT05897424
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
A Phase 2, Single Arm, Open Label Extension Study, Evaluating the Long-Term Safety and Clinical Efficacy of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
Sponsor
Sanofi
Enrollment
185 participants
Start Date
Jun 20, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Phase 2 open label extension study to evaluate SAR447537 (INBRX-101) in adults with AATD emphysema
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria5
- Males or females 18-80 years of age, inclusive, at the time of screening
- Diagnosis of AATD
- Evidence of emphysema secondary to AATD
- FEV1 of ≥ 30% predicted at screening and post-bronchodilator FEV1/FVC<0.7
- Current non-smoking status
Exclusion Criteria11
- For newly identified participants
- Receipt of A1PI augmentation therapy within 5 weeks prior to the first dose of study drug
- Known or suspected allergy to components of SAR447537, A1PI or human IgG
- Uncontrolled diabetes mellitus despite adequate antidiabetic pharmacologic treatment with a screening HbA1c value ≥9%
- Received IV immunoglobulins, monoclonal antibodies and/or other biologic therapies within 30 days
- On waiting list for lung or liver transplant
- Acute respiratory tract infection or COPD exacerbation within 4 weeks prior to or during screening
- Evidence of decompensated cirrhosis
- Active cancers or has a history of malignancy within 5 years prior to screening
- History of unstable cor pulmonale
- The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGSAR447537
A1PI, Recombinant, Bivalent Fc Fusion Protein
Locations(40)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05897424
Related Trials
A Multi Center Study Testing a New Implant for Adults With Severe Emphysema
NCT071192293 locations
A Trial of the Implantable Artificial Bronchus 50 Flex in Patients With Severe Emphysema
NCT070863392 locations
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
NCT0755548319 locations
Clinical-ultrasonographic Assessment of Pulmonary Emphysema
NCT065333714 locations
A Study of AIR-001 in Adults With Alpha-1 Antitrypsin Deficiency (AATD)
NCT074311124 locations